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MaBACKGROUND Graft patency is one of the major determinants of long-term outcome following coronary artery bypass
graft surgery (CABG). Biomarkers, if indicative of the underlying pathophysiological mechanisms, would suggest stra-
tegies to limit graft failure. The prognostic value of microvesicles (MVs) for midterm graft patency has never been tested.
OBJECTIVES The aim of this study was to evaluate whether MV pre-operative signature (number, cellular origin,
procoagulant phenotype) could predict midterm graft failure and to investigate potential functional role of MVs in graft
occlusion.
METHODS This was a nested case-control substudy of the CAGE (CoronAry bypass grafting: factors related to late
events and Graft patency) study that enrolled 330 patients undergoing elective CABG. Of these, 179 underwent coronary
computed tomography angiography 18 months post-surgery showing 24% graft occlusion. Flow cytometry MV analysis
was performed in 60 patients (30 per group with occluded [cases] and patent [control subjects] grafts) on plasma
samples collected the day before surgery and at follow-up.
RESULTS Before surgery, cases had 2- and 4-fold more activated platelet-derived and tissue-factor positive MVs
respectively than control subjects. The MV procoagulant capacity was also significantly greater. Altogether this MV
signature properly classified graft occlusion (area under the curve 0.897 [95% confidence interval: 0.81 to 0.98];
p < 0.0001). By using an MV score (0 to 6), the odds ratio for occlusion for a score above 3 was 16.3 (95% confidence
interval: 4.1 to 65.3; p < 0.0001).
CONCLUSIONS The pre-operative signature of MVs is independently associated with midterm graft occlusion in CABG
patients and a cumulative MV score stratifies patients’ risk. Because the MV signature mirrors platelet activation, patients
with a high MV score could benefit from a personalized antiplatelet therapy. (J Am Coll Cardiol 2020;75:2819–32)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C oronary artery bypass graft (CABG) surgeryis still the standard treatment of coronaryrevascularization for patients with severe
coronary artery disease (CAD) (1). Graft patency,N 0735-1097
m the aDepartment of Pharmaceutical Sciences, Università degli Studi di
CS, Milan, Italy; cDipartimento di Scienze Biomediche per la Salute, Un
CCS Policlinico San Donato, San Donato, Italy. This work was supported
alizzata 2013, PE-2013-02357476, to Prof. Camera). All other authors have
contents of this paper to disclose.
e authors attest they are in compliance with human studies committees
tutions and Food and Drug Administration guidelines, including patient co
JACC author instructions page.
nuscript received February 19, 2020; revised manuscript received Marchtogether with completeness of revascularization, is a
major determinant of long-term outcome following
CABG. The surgical procedure elicits a persistent sys-
temic inflammatory response associated with thehttps://doi.org/10.1016/j.jacc.2020.03.073
Milano, Milan, Italy; bCentro Cardiologico Monzino
iversità degli Studi di Milano, Milan, Italy; and the
by a grant from Italian Ministry of Health (Ricerca
reported that they have no relationships relevant to
and animal welfare regulations of the authors’ in-
nsent where appropriate. For more information, visit
13, 2020, accepted March 31, 2020.
ABBR EV I A T I ON S
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intervention
TF = tissue factor
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2820activation of the hemostatic system leading
to perturbation of endothelial and vascular
function and activation of platelets and leu-
kocytes (2). All of these events are the main
players responsible for the early and late
graft failure in a significant percentage of pa-
tients (1).
The availability of biomarkers able to pre-
dict graft occlusion would possibly suggest
strategies to limit graft failure. Several
studies aimed to identify predictors of early-
term graft occlusion after CABG focusing on
the presence of conventional risk factors,
genetic markers, features of coronary targets,or technical aspects. Other studies focused on plas-
matic biomarkers, such as perioperative inflamma-
tory and hemostatic factors (reviewed in Parolari
et al. [3]). We recently identified D-dimer as a
biomarker associated with medium-term graft occlu-
sion (4). The molecular mechanisms underlying the
modulation of these biomarkers are, however, often
unclear, thus limiting possible interventions to
improve the graft patency and hard outcomes.SEE PAGE 2833Circulating microvesicles (MVs) have received
increasing attention during the last years as novel
players in cardiovascular disease (5,6). MVs are small
membrane vesicles involved in cell-to-cell commu-
nication acting as biological messengers. MVs of
different origin are present in the circulation of
healthy subjects, and their number increases in
several pathological conditions contributing to the
development, progression, and clinical outcome of
diseases. They have been proposed as biomarkers of
thrombosis, vascular injury, and inflammation in
atherothrombosis and myocardial infarction, where
elevated levels have been correlated with disease
severity (7). Among the circulating MVs, those
expressing phosphatidylserine are defined as pro-
coagulant MVs (8). A subgroup of procoagulant MVs
also express tissue factor (TF) (9), the key activator of
the blood coagulation cascade. These procoagulant
MVs have a role in the prediction of cardiovascular
events (10,11) and are able to identify patients at high
recurrence risk (12). Thus far, many studies have
generated compelling data on the sensitivity of
circulating MVs as biomarkers of cardiovascular dis-
ease progression and events. The usefulness of MVs
in patients undergoing CABG, however, has only been
tested in 1 study that highlighted their importance insurgical hemostasis (13). No information is so far
available on the association between the amount or
pattern of circulating MVs and CABG outcome.
Thus, we carried out this study to: 1) elucidate
whether graft occlusion, evaluated 18 months after
CABG, associates with a specific signature of circu-
lating MVs in terms of number, cellular origin, and
procoagulant phenotype; 2) assess what MV signa-
ture analyzed before surgery could identify those
patients who will experience graft occlusion; and
3) investigate potential functional role of MVs in
graft occlusion based on their protein profile as well
as their procoagulant potential.
METHODS
STUDY DESIGN FOR MV ANALYSIS. The study took
advantage of an existing biobank of plasma samples
prepared from a cohort of 330 consecutive patients
enrolled for elective surgical myocardial revasculari-
zation between November 2006 and February 2010 at
Centro Cardiologico Monzino IRCCS (NCT00755248)
(Supplemental Figure 1) (5). The study was approved
by the Ethical Committee of Centro Cardiologico
Monzino IRCCS and was conducted according to the
Declaration of Helsinki. A written informed consent
was obtained from all the participants.
At 18-month follow-up, coronary computed to-
mography angiography (CTA) performed on 179 pa-
tients showed the presence of at least 1 occluded graft
in 43 subjects. Clinical outcomes at 52-month follow-
up was assessed by telephone interview. A nested
case-control study comparing age- and sex-matched
patients was designed to analyze MVs. Suitable sam-
ples were available from 30 of 43 patients with
occluded grafts (cases) at follow-up (n ¼ 6 plasma
were hemolyzed, n ¼ 2 plasma had fibrin clots, n ¼ 5
were missing), and were compared with 30 patients
with patent grafts (control subjects).
STATISTICAL ANALYSIS. Quantitative variables
were reported as mean  SD or median (interquartile
range [IQR]). Spearman’s correlation was used to find
monotonic association between variables. Categorical
variables were compared between the 2 groups by the
chi-square test, and quantitative variables by the
Wilcoxon rank-sum test. Multivariable logistic
regression was used to assess whether the MV levels,
measured at baseline, were independently associated
with future graft occlusion, after adjustment for the
variables significantly differing between cases and
control subjects. To summarize the overall potential
TABLE 1 Baseline Characteristics of the Patients Included in the Study
Cases (n ¼ 30) Control Subjects (n ¼ 30) p Value
Age, yrs 63  8 64  8 0.53
Male 27 (88) 26 (86) 0.70
Body mass index, kg/m2 25.4  2.4 27.5  3.6 0.005
Blood cell counts
Platelet count 260  72 236  59 0.15
Monocyte count 0.40  0.18 0.53  0.48 0.29
Granulocyte count 4.80  1.77 4.55  1.77 0.57
Lymphocyte count 2.00  0.63 2.14  0.45 0.41
Risk factors
Diabetes mellitus 7 (23) 9 (30) 0.56
Hypertension 25 (83) 24 (80) 0.95
Hyperlipidemia 24 (80) 23 (77) 0.76
Current smoker 7 (23) 4 (13) 0.39
Medications
Antiplatelet 19 (63) 16 (53) 0.40
Hypoglycemic 5 (17) 6 (20) 0.95
Antihypertensive 26 (86) 25 (83) 0.70
Antiarrhythmic 1 (3) 0 (2) 0.75
Hypolipidemic 20 (66) 18 (60) 0.50
Surgical parameters
Diseased coronary vessels 2.74  0.52 2.84  0.58 0.28
Great saphenous vein use 30 (100) 30 (100) 1.00
LIMA use 30 (100) 29 (97) 0.41
RIMA use 9 (30) 4 (13) 0.06
Radial artery use 2 (7) 0 (0) 0.07
Echocardiographic EF, % 54.7  11.5 58.1  7.9 0.15
Additive EuroSCORE 2.8  2.5 2.6  2.1 0.71
Logistic EuroSCORE 2.8  3.4 2.3  2.2 0.50
Surgery time, h 4.5  0.8 4.1  0.8 0.07
ECC time, min 109.8  39.1 100.2  25.9 0.23
Clamp time, min 77.0  31.3 69.1  19.0 0.20
Values are mean  SD or n (%).
ECC ¼ extracorporeal circulation; EF ¼ ejection fraction; LIMA ¼ left internal mammary artery; RIMA ¼ right
internal mammary artery.
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2821predictive ability of the 6 MV classes, a score was
constructed adding 1 point for each MV class with
levels above its median.
The ability of individual MV classes and of the
score to discriminate between patent and occluded
grafts at 18 months was assessed by receiver-
operating characteristic (ROC) curve analysis. SAS
statistical software version 9.4 (SAS Institute, Cary,
North Carolina) was used for all analyses, and a
p value <0.05 was considered statistically significant.
For the main analyses (logistic regression and ROC
curve analysis), the p value threshold for significance
was set at 0.0083, accounting for Bonferroni correc-
tion for 6 independent tests.
For a complete Methods section, including
Supplemental Tables 1 and 2, please see the
Supplemental Appendix.
RESULTS
PATIENT CHARACTERISTICS. Patients were divided
into 2 groups according to graft patency
(controls ¼ patent graft; cases ¼ occluded graft;
n ¼ 30 per group) assessed by coronary CTA
18 months after surgery. Their baseline characteris-
tics are summarized in Table 1. There were no sig-
nificant differences in age, sex, blood cell counts, risk
factors, and medications between the 2 groups as well
as in the number of diseased coronary vessels and the
vessels used for bypass grafting (Table 1). The rate of
occlusion between vein and artery grafts was also
similar (Supplemental Table 3).
At 18-month follow-up, all patients were on anti-
platelet therapy, cholesterol-lowering medications,
and beta-blockers (Supplemental Table 4), and no
difference in clinical outcomes was observed between
the 2 groups. Conversely, a significant higher occur-
rence of major adverse cardiovascular or cerebrovas-
cular events was observed in cases at 52-month
follow-up (Supplemental Table 5).
CHARACTERIZATION OF MICROVESICLE PHENOTYPE AT
18-MONTH FOLLOW-UP. Circulating MVs were studied
taking into account: 1) their total number; 2) their cell
origin, focusing on those derived from platelets,
granulocytes, monocytes, and endothelium; and
3) the expression of platelet activation markers
(CD62P and CD40L) and TF.
The relative amount of platelet-, leukocyte-, and
endothelium-derived MVs was similar in the 2 groups
of patients (w60%, 25%, 7%, and 8% of the total
amount of MVs for platelet-, granulocyte-, monocyte-,and endothelium-derived MVs, respectively). Despite
this, cases had a 2-fold higher number of total
circulating MVs compared with control subjects (1,658
MVs/ml [IQR: 1,034 to 3,022 MVs/ml] vs. 705 MVs/ml
[IQR: 389 to 863 MVs/ml], respectively; p ¼ 0.008)
(Figure 1A). MVs derived from platelets were the most
abundant and they were twice as abundant in cases
than in control subjects (p ¼ 0.019) (Table 2). A similar
difference was also observed in the number of gran-
ulocyte- and monocyte-derived MVs, but not in
endothelium-derived MVs (Table 2).
Interestingly, the number of MVs shed from acti-
vated platelets (CD62Pþ/CD41þ or CD40Lþ/CD41þ)
was 3 times greater in cases compared with control
subjects (p ¼ 0.003 for CD62Pþ/CD41þ and p ¼ 0.022
for CD40Lþ/CD41þ MVs). Similarly, the number of
FIGURE 1 Quantification of Circulating MVs in Patients Undergoing Elective CABG
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Microvesicle (MV) counts were evaluated by flow cytometry in platelet-free-plasma
collected at 18-month follow-up (A) and the day before coronary artery bypass graft
(CABG) surgery (B). Data are presented as a box plot, with median and 25th to 75th
percentiles (box) and min-max values (whiskers).
TABLE 2 Levels of Circulating MVs Measured 18 Months After
CABG Surgery
MV Cell Origin
Cases
(MVs/ml)
Control Subjects
(MVs/ml) p Value
CD41þ 939 (483–1,740) 460 (330–672) 0.019
CD66þ 489 (476–879) 178 (93–259) 0.021
CD14þ 103 (72–195) 79 (42–133) 0.034
CD31þ/CD41 104 (61–129) 98 (49–186) 0.904
Activated platelet-
derived MVs
CD62Pþ/CD41þ 108 (77–437) 32 (21–62) 0.003
CD40Lþ/CD41þ 73 (23–128) 29 (21–45) 0.022
TFþ MVs
Total TFþ 204 (128–569) 97 (39–168) 0.0004
TFþ/CD41þ 33 (19–50) 21 (7–29) 0.014
TFþ/CD66þ 128 (101–220) 47 (25–115) 0.119
TFþ/CD14þ 31 (12–40) 11 (5–21) 0.009
TFþ/CD31þ/CD41 33 (5–70) 12 (9–19) 0.326
Values are median (interquartile range). Controls are patients who would have had
patent graft at follow-up; cases are patients who would have had occluded graft at
follow-up.
CABG ¼ coronary artery bypass graft; CD14þ ¼ monocyte-derived; CD31þ/
CD41 ¼ endothelium-derived; CD40L ¼ CD40 ligand; CD41þ ¼ platelet-derived;
CD62P ¼ P-selectin; CD66þ ¼ granulocyte-derived;. MVs ¼ microvesicles;
TF ¼ tissue factor.
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2822total TFþ MVs was also higher (2-fold; p ¼ 0.0004) in
cases compared with control subjects (Table 2).
Overall, these data suggest that in patients with
occluded grafts, the number of activated platelet-
derived MVs and of TFþ MVs is significantly greater
compared with patients with a patent graft.
CHARACTERIZATION OF MICROVESICLE PHENOTYPE
BEFORE CABG SURGERY. We then assessed whether an
association exists between circulating MV composi-
tion before surgery and bypass graft occlusion at
follow-up. Before surgery, cases showed a trend to-
ward higher levels of total MVs compared with con-
trols, although the difference was not statistically
significant (Figure 1B).In terms of cell origin, no differences were
observed in the number of leukocyte- and
endothelium-derived MVs between the 2 cohorts of
patients (Table 3). Conversely, a 2-fold higher number
of platelet-shed MVs was observed in cases
(p ¼ 0.020), similarly to that reported at follow-up. Of
interest, no correlation was found between platelet
blood counts and platelet-derived MV levels (r ¼ 0.10;
p ¼ 0.500), suggesting a higher MV release per cell
and, therefore, a higher cell activation state. Indeed,
the number of CD62Pþ/CD41þ MVs, which correlated
with that of CD40Lþ/CD41þ MVs (r ¼ 0.53;
p ¼ 0.0004), was higher in cases (p ¼ 0.042 and
p ¼ 0.026, respectively). Moreover, before CABG,
cases also had 4 times more TFþ MVs compared with
control subjects (p ¼ 0.05), and those derived from
platelets were 3-fold higher (p ¼ 0.003) (Table 3).
All together these results support the evidence that
a significantly higher platelet activation state char-
acterizes patients who will experience graft failure at
follow-up.
PLASMA PROTEIN PROFILE AND FUNCTIONAL
ANNOTATION ANALYSIS. The higher platelet acti-
vation state highlighted in cases through MV analysis
was further supported by a global plasma protein
profile performed on the same samples. Pre-surgery
levels of 92 cardiovascular disease-related
TABLE 3 Levels of Circulating MVs Measured Before CABG Surgery
MV Cell Origin Cases (MVs/ml) Control Subjects (MVs/ml) p Value
CD41þ 1,171 (493–3,008) 750 (158–1,788) 0.020
CD66þ 591 (372–600) 324 (134–492) 0.290
CD14þ 140 (59–343) 120 (41–186) 0.070
CD31þ/CD41- 62 (42–102) 145 (56–233) 0.133
Activated platelet-derived MVs
CD62Pþ/CD41þ 263 (167–720) 160 (99–310) 0.042
CD40Lþ/CD41þ 143 (71–405) 79 (24–103) 0.026
TFþ MVs
Total TFþ 422 (171–804) 106 (56–446) 0.050
TFþ/CD41þ 48 (27–70) 17 (10–28) 0.003
TFþ/CD66þ 187 (114–258) 53 (38–69) 0.192
TFþ/CD14þ 33 (18–69) 17 (9–41) 0.038
TFþ/CD31þ/CD41- 13 (12–29) 36 (11–63) 0.236
Values are median (interquartile range).
Abbreviations as in Table 2.
TABLE 4 Pre-Surgery Levels of Plasma Proteins Differentially Expressed in Cases and
Control Subjects
Protein Symbol ID Uniprot Protein Name Log2 FC p Value
CXCL1 P09341 C-X-C motif chemokine 1 0.282 0.0011
HB-EGF Q99075 Heparin-binding EGF-like growth factor 0.124 0.0015
HSP 27 P04792 Heat shock 27 kDa protein 0.577 0.0033
Dkk-1 O94907 Dickkopf-related protein 1 0.224 0.0033
VEGF-A P15692 Vascular endothelial growth factor A 0.046 0.0051
PDGF Subunit B P01127 Platelet-derived growth factor subunit B 0.326 0.0058
CD40 P25942 Tumor necrosis factor receptor
superfamily member 5
0.089 0.0062
CASP-8 Q14790 Caspase-8 0.664 0.0062
SIRT2 Q8IXJ6 SIR2-like protein 2 0.593 0.0086
CD40-L P29965 CD40 ligand 0.285 0.0092
PAR-1 P25116 Proteinase-activated receptor 1 0.095 0.0105
MMP-1 P03956 Matrix metalloproteinase-1 0.627 0.0105
EGF P01133 Epidermal growth factor 0.406 0.0112
TNFSF14 O43557 Tumor necrosis factor ligand
superfamily member 14
0.213 0.0112
NEMO Q9Y6K9 NF-kappa-B essential modulator 0.357 0.0127
PAPPA Q13219 Pappalysin-1 -0.271 0.0172
U-PAR Q03405 Urokinase plasminogen activator
surface receptor
0.017 0.0245
AGRP O00253 Agouti-related protein 0.070 0.0307
Differentially expressed protein are reported. Data are expressed as fold changes (log2 FC) (see Methods section).
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2823biomarkers showed that 20 proteins were associated
with graft failure after adjustment for multiple com-
parisons. In particular, 18 proteins were overex-
pressed before surgery in plasma of cases (Table 4).
Analysis of the biological pathways in which these
proteins are mainly involved (Table 5) indicated that 7
proteins are associated with the hemostatic/throm-
botic process, in particular, platelet activation (5 of
20; p ¼ 0.028) and degranulation (3 of 20; p ¼ 0.05),
whereas 5 proteins are involved in the inflammatory
response (p ¼ 0.042). Processes such as positive
regulation of cell migration and proliferation
(p ¼ 0.045) and cell division (p ¼ 0.042) are also
involved.
Taken together, these data confirm that processes
strictly related to the progression of atherosclerosis,
such as platelet activation, inflammation, cell
migration, and proliferation, are more activated in
patients who will experience bypass graft failure
compared with those who will have patent graft at
follow-up.
THROMBIN GENERATION CAPACITY OF MVs
BEFORE CABG SURGERY. Thrombin plays an impor-
tant role not only in coagulation, but also in processes
such as inflammation and cell proliferation, mecha-
nisms involved in graft failure. Thus, we analyzed the
pre-surgery thrombin generation potential of MVs
from cases and control subjects.
MVs from cases generated a higher amount of
thrombin compared with control subjects (peak: 323.8
 102.8 nmol/l vs. 245.0  106.9 nmol/l; p ¼ 0.04,
respectively) with a faster kinetic rate (velocity index:
134.3  68.2 nmol/l/min vs. 87.1  57.7 nmol/l/min;
p ¼ 0.05, respectively) (Figure 2). Interestingly, the
endogenous thrombin potential (ETP) correlated with
the number of procoagulant annexin Vþ (AnVþ)/TFþ
MVs (r ¼ 0.40; p ¼ 0.03).
Flow cytometric enumeration of procoagulant MVs
showed that cases had a double number of AnVþ/TFþ
MVs (Figure 3), which derived mainly from platelets
and granulocytes. However, although the number of
AnVþ/TFþ MVs released from granulocytes was not
different between cases and control subjects, the
number of procoagulant AnVþ/TFþMVs released from
platelets was significantly higher in cases compared
with control subjects (p ¼ 0.001) accounting for 72 
12% and 48  18% of the total AnVþ/TFþ MVs,
respectively (Figure 3).
These data, underscoring the greater pro-
thrombotic profile of MVs found in patients who will
experience graft failure at follow-up, provide insights
into the potential mechanisms involved in the loss of
patency.ASSOCIATION OF BASELINE MVs WITH CABG
OCCLUSION. Among the 13 MV classes analyzed before
CABG, 6 of them—including those derived from acti-
vated platelets (CD40Lþ/CD41þ, CD62Pþ/CD41þ, TFþ/
CD41þ) and the procoagulant MVs (TFþ, AnVþ/TFþ,
and platelet-derived AnVþ/TFþ MVs)—significantly
discriminated between cases and control subjects in
ROC curve analysis, with areas under the curve
TABLE 5 Functional Annotation Analysis
Biological Process
Adjusted p Value
(BH) ID Uniprot Protein Name
Platelet activation 0.028 C369965 CD40LG
P25942 CD40 molecule
P12931 SRC proto-oncogene, nonreceptor
tyrosine kinase
P25116 F2R
P01133 EGF
Platelet degranulation 0.05 P16284 PECAM1
P01127 PDGFB
P15692 VEGFA
Inflammatory response 0.042 P09341 CXCL1
P29965 CD40LG
P25942 CD40 molecule
P25116 F2R
Q9Y6K9 IKBKG
Positive regulation of cell
migration
0.045 P25116 F2R
Q99075 HBEGF
P01127 PDGFB
P15692 VEGFA
Positive regulation of cell
proliferation
0.045 P25116 F2R
P01133 EGF
Q99075 HBEGF
P01127 PDGFB
P15692 VEGFA
Positive regulation of cell
division
0.042 P01127 PDGFB
Q8IXJ6 SIRT2
P15692 VEGFA
Negative regulation of
apoptotic process
0.044 P29965 CD40LG
P12931 SRC proto-oncogene, nonreceptor
tyrosine kinase
P04792 HSPB1
Q03405 PLAUR
P15692 VEGFA
Immune response 0.04 P09341 CXCL1
P29965 CD40LG
P25942 CD40 molecule
Q9Y6K9 IKBKG
O43557 TNFSF14
Proteins are grouped according to the biological process in which they are involved.
CD40LG ¼ CD40 ligand; CXCL1 ¼ C-X-C motif chemokine ligand 1; EGF ¼ epidermal growth factor;
F2R ¼ coagulation factor II thrombin receptor; HBEGF ¼ heparin-binding EGF-like growth factor; HSPB1 ¼ heat
shock protein family B (small) member 1; IKBKG ¼ inhibitor of kappa light polypeptide gene enhancer in B cells,
kinase gamma; PDGFB ¼ platelet-derived growth factor subunit B; PECAM1 ¼ platelet and endothelial cell
adhesion molecule 1; PLAUR ¼ plasminogen activator, urokinase receptor; SIRT2 ¼ Sirtuin 2; TNFSF14 ¼ tumor
necrosis factor superfamily member 14; VEGFA ¼ vascular endothelial growth factor A.
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2824(AUCs) ranging from 0.74 to 0.81 (Figure 4). When the
discriminant ability of these MVs was evaluated on
top of body mass index (the only baseline variable
significantly different between the 2 groups) the AUC
increase remained significant for all MV subtypes, butnot for CD62Pþ/CD41þ (p ¼ 0.085) (Supplemental
Figure 2, Supplemental Table 6).
To summarize the overall MV discriminating abil-
ity, the 6 MV classes mentioned previously (procoa-
gulant and activated platelet-derived MVs) were
combined in the MV score (see Methods section for
details). Results showed that all patients with a
score <2 would have had a patent graft after
18 months, whereas all patients with a score of 6
would have had an occluded graft (Supplemental
Figure 3). The median MV score was indeed 1 (IQR:
0 to 3) and 4.5 (IQR: 4 to 5) in control subjects and
cases, respectively (p < 0.0001). For a score above the
overall median value of 3, the adjusted OR for oc-
clusion was 16.3 (95% confidence interval [CI]: 4.1 to
65.3; p < 0.0001). Using the same cutoff, the MV score
was able to correctly classify cases and control sub-
jects with a sensitivity of 77.3% and a specificity of
82.8%. Of interest, the AUC for the MV score was
higher than the AUC for any single MV class (AUC
0.897; 95% CI: 0.81 to 0.98) (Figure 5).
The discriminant capability of MVs and of MV score
was compared with that of D-dimer, a recently
demonstrated independent predictor of midterm
graft occlusion (4). The AUCs of the single MVs were
not significantly different from that of D-dimer (all
p > 0.24). When the discriminant ability of MVs was
analyzed on top of D-dimer, the procoagulant MVs
increased the AUC (Table 6), but did not reach the
Bonferroni statistical significance. Of note, AUC for
the MV score added on top of D-dimer levels was
significantly higher than that of D-dimer alone
(þ0.18; 95% CI: þ0.05 to þ0.31; p ¼ 0.007) but similar
to that of the MV score alone (þ0.01; 95% CI: 0.02
to þ0.04; p ¼ 0.38) (Figure 5).
DISCUSSION
The present study provides, for the first time, the
evidence that the pre-surgical signature of circu-
lating MVs is independently associated with
midterm graft occlusion in patients undergoing
CABG (Central Illustration). Levels of platelet-
derived and procoagulant MVs are significantly
greater in patients who will experience graft failure
compared with patients with patent grafts, and a
cumulative MV score, based on the MV phenotypic
characterization, stratifies patients’ risk. Because
the MV signature mirrors the activated state of
circulating platelets, patients with a high pre-
surgery MV score could benefit from additional
FIGURE 2 Thrombin Generation Capacity of MVs
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Prothrombotic potential of microvesicles (MVs) from cases and control subjects was analyzed by thrombin generation assay (calibrated automated thrombogram
[CAT]). (A) Curves obtained in a representative experiment. Curves generated in the absence of MVs (MV free plasma [FP], dotted lines) are shown for comparison. (B)
Peak height (maximum concentration of generated thrombin) and (C) velocity index (velocity of thrombin formation) were used as main parameters describing thrombin
generation. Data reported in the histograms are expressed as mean  SD.
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thrombin generation.
Graft occlusion 1 year after surgery affects a
consistent number of patients with a 11% rate of
saphenous vein graft occlusion (14) despite the best
pharmacological treatment as per guidelines (15,16).
The identification of patients who are at risk of graft
failure continues to be challenging. Several bio-
markers correlate with graft occlusion. Among plasma
biomarkers, pre-operative levels of C-reactive pro-
tein, interleukin-6, F1þ2, tissue plasminogenactivator, and FVIII predict early graft occlusion (3),
whereas D-dimer has a prognostic value in midterm
graft failure (4).
The role of biomarkers in outcome prediction of
CABG is, however, still controversial due to several
limitations in the published studies (3). The “ideal”
biomarkers should not only be useful in assessing the
risk of negative outcome, but should also prompt the
adoption of (pharmacological) strategies to limit graft
failure. To this aim, however, biomarkers should
provide the link between their changes and the
FIGURE 3 Analysis of Procoagulant AnVþ/TFþ MVs
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Number of AnVþ/tissue factor (TF)þ microvesicles (MVs) was measured in control subjects and cases before coronary artery bypass graft
(CABG). The amount of procoagulant MVs derived from monocytes (CD14þ, blue), granulocytes (CD66þ, red), and platelets (CD41þ, black) is
reported.
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2826underlying pathophysiological mechanisms. Deter-
mination of the previously mentioned plasmatic bio-
markers does not identify the molecular mechanisms
and/or the dysfunctional cell population involved.
Conversely, MV signature provides a direct link be-
tween the MV’s phenotype and the parental cell/cells.
Circulating MVs shed from cells of the vascular
compartment indeed reflect the presence of activated
cells in vivo, as documented in several pathophysio-
logical conditions, including cardiovascular disease
(17). Mallat et al. (18) in 2000 showed that patients
with acute coronary syndrome have a greater number
of procoagulant MVs compared with patients with
stable angina or other non-CAD control subjects (18).
They also first proposed that levels of circulating MVs
could be a prognostic marker of the recurrence of
ischemic events.
Over the years, other studies confirmed that the
higher MV levels found in patients with CAD corre-
lated with the severity of disease (6,19). Interestingly,
it has been reported that in patients with myocardial
infarction, the amount of procoagulant and platelet-
derived MVs were significantly reduced after suc-
cessful revascularization with percutaneous coronary
intervention (PCI) (20). We observed the same trendin our study. Patients with patent grafts 18 months
after CABG had a significantly lower number of
circulating MVs compared with patients with
occluded grafts, in whom MVs were as high as the
pre-surgery levels. Interestingly, before CABG, the
number of MVs was similar in cases and control sub-
jects, indicating that the total count of MVs per se
does not have a prognostic value.
Only the detailed phenotypic pre-surgery signature
provided the information needed to discriminate be-
tween cases and control subjects and to stratify the
patient’s risk at follow-up. Patients with
graft failure have twice the number of activated
platelet-derived MVs (CD40Lþ/CD41þ, CD62Pþ/
CD41þ, TFþ/CD41þMVs) and 4-fold more procoagulant
MVs (TFþ, AnVþ/TFþ, and platelet-derived AnVþ/
TFþ MVs) compared with patients with patent graft.
No differences were observed in the number of
leukocyte- and endothelium-derived MVs between
the 2 cohorts of patients. Thus, the MV signature
found in cases clearly reflected a platelet activation
status that was also confirmed by a global plasma
protein profile. In cases, we found a pre-surgery up-
regulation of 18 proteins involved not only in platelet
activation, but also in inflammatory response and in
FIGURE 4 ROC Curve Analysis of MVs Versus Future Graft Occlusion
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Receiver-operating characteristic (ROC) curve analysis was used to evaluate the potential prognostic value of the baseline number of activated platelet-
derived MVs (CD40Lþ/CD41þ, CD62Pþ/CD41þ, and TFþ/CD41þ MVs) and procoagulant MVs (TFþ, AnVþ/TFþ, and CD41þ/TFþ/AnVþ MVs) for CABG oc-
clusion. Area under the curve (AUCs), p value for AUC differences, cut-off value, sensitivity, and specificity are reported. Abbreviations as in Figure 3.
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FIGURE 5 ROC Curve Analysis of MV Score Versus Future Graft Occlusion
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An MV score was elaborated to summarize the overall association of the 6 MV classes
(CD40Lþ/CD41þ, CD62Pþ/CD41þ, TFþ/CD41þ, TFþ, AnVþ/TFþ, and AnVþ/CD41þ/TFþ
MVs) with future graft occlusion (see Methods section for details). Results of ROC curve
analysis, comparing the AUC of the MV score with that of D-dimer levels, are shown.
AUC and p value for AUC differences are reported. Abbreviations as in Figures 3 and 4.
TABLE 6 Compariso
MVs
D-dimer
CD40Lþ /CD41þ
CD40Lþ /CD41þ
CD62Pþ/CD41þ
CD62Pþ/CD41þ
TFþ/CD41þ
TFþ/CD41þ
TFþ
TFþ
AnVþ/TFþ
AnVþ/TFþ
AnVþ/CD41þ/TFþ
AnVþ/CD41þ/TFþ
Bold p values are statistica
ations as in Table 2.
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2828cell proliferation and migration. These processes are
well known to be sustained by activated platelets in
the setting of atherothrombosis (21) and graft occlu-
sion (22,23). Several studies have also shown thatn of the Discriminant Ability of MVs With That of D-Dimer
AUC (95% CI)
p Value vs.
D-Dimer
0.72 (0.58–0.86)
0.80 (0.67–0.93) 0.548
on top of D-dimer 0.83 (0.71–0.96) 0.129
0.77 (0.62–0.91) 0.948
on top of D-dimer 0.82 (0.69–0.95) 0.237
0.81 (0.69–0.93) 0.333
on top of D-dimer 0.86 (0.76–0.97) 0.027
0.78 (0.65–0.91) 0.443
on top of D-dimer 0.85 (0.75–0.96) 0.039
0.81 (0.69–0.93) 0.241
on top of D-dimer 0.86 (0.77–0.96) 0.015
0.74 (0.60–0.88) 0.795
on top of D-dimer 0.85 (0.75–0.95) 0.026
lly significant. AUC ¼ area under the curve; CI ¼ confidence interval; other abbrevi-platelet-derived MVs, thanks to their capacity to
transfer proteins, lipids, and nucleic acids to recipient
cells, can actively participate in the same processes
(24). In addition, they can promote thrombin forma-
tion that, besides its central role in hemostasis and
thrombosis, is involved in cell proliferation, angio-
genesis, and inflammation (25) and is implicated in
post-angioplasty restenosis through induction of
VSMC proliferation (22).
Thus, to analyze one of the potential functional
roles of MVs in graft occlusion, we assessed the ca-
pacity of MVs from cases and control subjects to
generate thrombin. Patients with occluded grafts
showed a significantly higher pre-surgical thrombin
generation capacity, which correlated with the
amount of procoagulant Annþ/TFþ MVs, compared
with that of control subjects.
These findings bolster the increased levels of
D-dimer, marker of activation of coagulation, that
we previously reported in cases (4) and highlight
that a significantly higher prothrombotic status
characterizes patients who will experience graft
failure. This has been attributed to acute throm-
bosis within the first month, intimal hyperplasia up
to 1 year, and atherosclerosis beyond 1 year (23).
Although the coronary CTA scan used to assess graft
patency at follow-up could not provide information
whether a thrombotic or stenotic process was
responsible for the graft occlusion, the overall data
of the present study are certainly indicative of a
pathophysiological status that could sustain both
processes.
Remarkably, D-dimer pre-surgery levels were
significantly associated with loss of graft patency
discriminating cases and control subjects with a
specificity and sensitivity comparable to that of
each of the 6 MV classes. However, a significantly
higher potential predictive ability was observed
when MV classes were considered together in a
cumulative MV score that provided the best prog-
nostic value with an area under the ROC curve of
0.897 (p < 0.0001). Moreover, the MV score
(ranging from 0 to 6 based on the classes of MVs
present in the plasma samples) allowed patients’
risk stratification showing a 16-fold higher risk of
graft occlusion for a score higher than 3.
Interestingly, Suades et al. (26) recently reported
the additive value of the multipanel approach, as
the one used in this study, in ST-segment elevation
myocardial infarction prediction. The combination
of distinct MV subsets was indeed significantly su-
perior in predicting ST-segment elevation myocar-
dial infarction than 1 type of MV alone (26). Our
CENTRAL ILLUSTRATION Capacity of Pre-Coronary Artery Bypass Graft Microvesicle Signature to Detect Midterm
Graft Occlusion
Camera, M. et al. J Am Coll Cardiol. 2020;75(22):2819–32.
Microvesicle (MV) signature was assessed in pre-surgery plasma samples of patients undergoing coronary artery bypass grafting (CABG). In patients with graft oc-
clusion 18 months after surgery (in red), the MV signature highlighted a higher platelet activation state compared with patients with patent grafts in the follow-up (in
blue). Interestingly, the pre-surgery MV signature was independently associated with midterm graft occlusion, thus suggesting that circulating MVs might represent a
useful biomarker to implement stratification of high-risk patients. The identification of platelet activation status, documented before surgery, may help the clinician to
tailor a personalized antiplatelet treatment. This future perspective has to be addressed in an ad hoc designed clinical trial. ASA ¼ aspirin; AUC ¼ area under the
curve; DAPT ¼ dual antiplatelet therapy.
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2830study, providing for the first time data in patients
undergoing CABG, adds new evidence that MVs are
independent markers of increased risk of cardio-
vascular events in high-risk patients (11,26). Indeed,
cases showed a higher occurrence of major adverse
cardiovascular or cerebrovascular events at 52-
month follow-up. Moreover, the MV signature has
a 2-fold clinical utility in this setting: by both
providing information in risk assessment and high-
lighting platelet activation as the underlying path-
ophysiological mechanism, it could help in the
evaluation of efficacy of different strategies to limit
graft failure, such as a more intensive antiplatelet
therapy.
Guidelines recommend aspirin monotherapy after
CABG to maintain graft patency and prevent athero-
thrombotic complications (15,16). Dual antiplatelet
therapy (DAPT) consisting of aspirin and a P2Y12 re-
ceptor inhibitor in the setting of CABG is a controver-
sial issue. It is recommended only in patients
undergoing CABG after acute coronary syndrome,
whereas there is currently no evidence of a survival
benefit or a reduction of thromboembolic complica-
tions with DAPT in patients with stable CAD undergo-
ing CABG (15).
The pharmacological approach used after the 2main
myocardial revascularization procedures, CABG and
PCI, deserves some consideration. Although they both
elicit a sustained platelet activation that deeply affects
the outcome, DAPT represents the cornerstone of
treatment in patients undergoing elective PCI,
whereas its effect in the setting of CABG has not been
definitely confirmed yet (15). Several reasons may ac-
count for the inconsistency in previous trials’ data,
including small sample sizes, heterogeneous pop-
ulations, and post-hoc analysis with low statistical
power. The most recent data, however, suggest that
DAPT may have a role in preventing graft occlusion.
Results of meta-analyses, carried out to compare graft
patency in patients treated with aspirin alone or
aspirin þ clopidogrel after CABG, suggest that DAPT
was associated with a significant reduction in saphe-
nous vein graft occlusions (27–29). This finding has
been recently confirmed by Zhao et al. (30) in a multi-
center open-label clinical trial on 500 elective CABG
patients carried out to compare the effect of
ticagrelor þ aspirin versus monotherapy with either
aspirin or ticagrelor. The results showed that DAPTwas
superior in maintaining saphenous vein graft patency
for up to 1 year in both patients with ACS and stable
CAD (30).In the era of precision medicine and of a contin-
uous effort to identify patients with the greatest
cardiovascular risk, availability of biomarkers with
high predictive value is of paramount importance
(31). If the results of the present study will be
confirmed in a larger population, it is tempting to
speculate that the MV signature could help physician
to tailor the antiplatelet therapy accordingly.
STUDY LIMITATIONS. Our findings should be inter-
preted in the context of their limitations. First, being
based on a relatively small sample size and a single
dataset, our results should be considered hypothesis-
generating: undoubtedly, is most likely that, in the
absence of a validation dataset, our results may have
a considerable bias, with a substantial overestimation
of true AUCs. Second, the thrombin generation ca-
pacity of MVs has been assessed on the whole plasma
and not on isolated MVs. Because cells release not
only MVs but also exosomes (32), we cannot exclude
that these vesicles also participate in the process.
Finally, assessment of graft patency by coronary CTA
scan has been performed only at 18-month follow-up;
thus, we cannot rule out the possibility that graft
failure occurred even before that time.
CONCLUSIONS
We report that CABG-treated patients who will expe-
rience mid-term graft occlusion are characterized by a
pre-surgery MV signature indicative of a platelet
activation status and supporting a greater thrombin
generation capacity compared to that of patients
with patent grafts. Thrombin, in addition to its role
in coagulation, can sustain inflammatory and cell
proliferation processes that lead to graft failure. The
pre-operative signature of MVs is an independent
predictor of midterm graft occlusion in CABG pa-
tients and a cumulative MV score stratifies patients’
risk. Because the MV signature mirrors an ongoing
platelet activation, patients with a high MV score
would benefit from a personalized antiplatelet
therapy.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In patients undergoing CABG
surgery, pre-operative circulating microvesicles are
associated with platelet activation and risk of subsequent
graft occlusion.
TRANSLATIONAL OUTLOOK: Future studies should
address whether risk stratification based on microvesicle
characterization can be employed to guide the intensity
of antiplatelet therapy and improve long-term clinical
outcomes in patients undergoing CABG surgery.
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